A Biobehavioral/Cognitive Treatment for Stress, Depression, and Anxiety in Patients With Stage IV Lung Cancer
This phase IIb trial studies the effect of a biobehavioral/cognitive (ABC) treatment on stress, depression, and anxiety in patients with stage IV lung cancer. Advanced lung cancer and stress or depression are associated with increased inflammation and decreased immunity. ABC is a combination of biobehavioral intervention, which studies the interaction between behavioral and biological processes, and cognitive therapy for the treatment for anxiety and depressive disorders. Giving ABC during lung cancer treatment may reduce stress, depression, and anxiety, and improve patients' quality of life and health.
Checked against the public recordLast updated Oct 23, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Interventions being studied
- Other: Behavioral, Psychological or Informational Intervention; Procedure: Biospecimen Collection; Other: Electronic Health Record Review; Other: Informational Intervention; Other: Survey Administration
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Individuals diagnosed with advanced (stage IV) lung cancer with diagnosis and staging confirmed by pathology report * Moderate to severe symptoms of depression (\>= 8 on Patients Health Questionaire-9) and/or moderate to severe symptoms of anxiety (\>= 10 on Generalized Anxiety Disorder-7; GAD-7) * English-speaking * Willingness to provide access to medical records, provide biospecimens, and responses to patient reported outcome (PRO) assessments * Ability to understand and willingness to sign an informed consent document Exclusion Criteria: * Patients to be treated with definitive chemo-radiotherapy * Presence of untreated brain metastases * Previous lung cancer diagnosis * Presence of disabling hearing, vision, or impairing psychiatric conditions (e.g., psychosis, bipolar disorder, substance abuse) preventing consent or completion of self-report measures in English * Imminent risk of suicide that precludes outpatient treatment * Currently receiving psychological treatment/counseling
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 23, 2023. Always confirm current availability with the study team.